These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 22182972)

  • 1. Tumor control versus adverse events with targeted anticancer therapies.
    Keefe DM; Bateman EH
    Nat Rev Clin Oncol; 2011 Dec; 9(2):98-109. PubMed ID: 22182972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dermatologic Adverse Events of Systemic Anticancer Therapies: Cytotoxic Chemotherapy, Targeted Therapy, and Immunotherapy.
    Deutsch A; Leboeuf NR; Lacouture ME; McLellan BN
    Am Soc Clin Oncol Educ Book; 2020 May; 40():485-500. PubMed ID: 32421446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer genomics guide clinical practice in personalized medicine.
    Lehmann-Che J; Poirot B; Boyer JC; Evrard A
    Therapie; 2017 Sep; 72(4):439-451. PubMed ID: 28258721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to report toxicity associated with targeted therapies?
    Cabarrou B; Boher JM; Bogart E; Tresch-Bruneel E; Penel N; Ravaud A; Escudier B; Mahier Ait-Oukhatar C; Delord JP; Roché H; Filleron T
    Ann Oncol; 2016 Aug; 27(8):1633-8. PubMed ID: 27217543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential Successes and Challenges of Targeted Cancer Therapies.
    Keefe DMK; Bateman EH
    J Natl Cancer Inst Monogr; 2019 Aug; 2019(53):. PubMed ID: 31425592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fear of Cancer Recurrence in an Era of Personalized Medicine.
    Thewes B; Husson O; Poort H; Custers JAE; Butow PN; McLachlan SA; Prins JB
    J Clin Oncol; 2017 Oct; 35(29):3275-3278. PubMed ID: 28723231
    [No Abstract]   [Full Text] [Related]  

  • 8. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
    Dietel M; Jöhrens K; Laffert MV; Hummel M; Bläker H; Pfitzner BM; Lehmann A; Denkert C; Darb-Esfahani S; Lenze D; Heppner FL; Koch A; Sers C; Klauschen F; Anagnostopoulos I
    Cancer Gene Ther; 2015 Sep; 22(9):417-30. PubMed ID: 26358176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine.
    Bashraheel SS; Domling A; Goda SK
    Biomed Pharmacother; 2020 May; 125():110009. PubMed ID: 32106381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral Mucosal Injury Caused by Targeted Cancer Therapies.
    Carrozzo M; Eriksen JG; Bensadoun RJ; Boers-Doets CB; Lalla RV; Peterson DE
    J Natl Cancer Inst Monogr; 2019 Aug; 2019(53):. PubMed ID: 31425602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychosocial Impact of Personalized Therapies in Oncology.
    Schilling G; Schulz-Kindermann F
    Recent Results Cancer Res; 2018; 210():181-190. PubMed ID: 28924686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Precision Medicine and Targeted Therapies in Breast Cancer.
    Greenwalt I; Zaza N; Das S; Li BD
    Surg Oncol Clin N Am; 2020 Jan; 29(1):51-62. PubMed ID: 31757313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapies: how personal should we go?
    Martini M; Vecchione L; Siena S; Tejpar S; Bardelli A
    Nat Rev Clin Oncol; 2011 Nov; 9(2):87-97. PubMed ID: 22083042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse events of targeted anticancer therapies: what radiologists need to know.
    López Sala P; Alberdi Aldasoro N; Unzué García-Falces G
    Radiologia (Engl Ed); 2020; 62(3):229-242. PubMed ID: 32057481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy in cancer.
    Tsimberidou AM
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1113-32. PubMed ID: 26391154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conquering the challenges of genotypic and phenotypic tumor heterogeneity to realize the promise of personalized cancer therapy: the role of academia.
    Merajver S; Phadke S; Soellner M
    Trans Am Clin Climatol Assoc; 2017; 128():169-179. PubMed ID: 28790501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current updates on precision therapy for breast cancer associated brain metastasis: Emphasis on combination therapy.
    Raza M; Kumar N; Nair U; Luthra G; Bhattacharyya U; Jayasundar S; Jayasundar R; Sehrawat S
    Mol Cell Biochem; 2021 Sep; 476(9):3271-3284. PubMed ID: 33886058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies For Clinical Implementation: Precision Oncology At Three Distinct Institutions.
    Nadauld LD; Ford JM; Pritchard D; Brown T
    Health Aff (Millwood); 2018 May; 37(5):751-756. PubMed ID: 29733728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
    Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
    Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of the NCI precision medicine trials-NCI MATCH and MPACT.
    Do K; O'Sullivan Coyne G; Chen AP
    Chin Clin Oncol; 2015 Sep; 4(3):31. PubMed ID: 26408298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.